Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234608 | 0.82 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL3920693 | 0.81 | TAAR1 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL3925426 | 0.80 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4991324 | 0.79 | SLC6A2 (0.56) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL1152681 | 0.79 | EPHX1 (0.45) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL1661396 | 0.79 | EPHX1 (0.45) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3718795 | 0.78 | SLC6A2 (0.48) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL27955989 | 0.77 | SLC6A2 (0.64) | SLC6A4SLC6A3SLC6A2LMNACNR1 | |
| SCHEMBL1661394 | 0.77 | EPHX1 (0.47) | SLC6A4SLC6A3SLC6A2LMNACYP2D6 | |
| SCHEMBL1153151 | 0.77 | EPHX1 (0.47) | SLC6A4SLC6A3SLC6A2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SUNOVION PHARMACEUTICALS INC (US) | 2015-10-22 | — | — | US | disclosed |
| US-9072700-B2 | Methods of using derivatives of (−)-venlafaxine | SUNOVION PHARMACEUTICALS INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140121283-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | SUNOVION PHARMACEUTICALS INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8642662-B2 | Methods of using derivatives of (−)-venlafaxine | SUNOVION PHARMACEUTICALS INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120302794-A1 | Derivatives of venlafaxine and methods of preparing and using the same | JERUSSI THOMAS P (US) | 2012-11-29 | — | — | US | disclosed |
| US-8269040-B2 | O-desmethylvenlafaxine succinate; tablet, capsule; sustained release; hydroxypropylmethyl cellulose rate controlling polymer; microcrystalline cellulose binder; depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease | WYETH LLC (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120232157-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | JERUSSI THOMAS P (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2133325-A1 | Derivatives of venlafaxine and methods of preparing and using the same | Sepracor Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20080269166-A2 | DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SEPRACOR INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1953136-A1 | Derivatives of (-)-venlafaxine and methods of preparing and using the same | Sepracor, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1466889-A1 | Derivatives of venlafaxine and methods of preparing and using the same | Sepracor Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180952-A1 | Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same | SEPRACOR INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040106576-A1 | Derivatives of venlafaxine and methods of preparing and using the same | SEPRACOR INC. (US) | 2004-06-03 | — | — | US | disclosed |
| US-20030018083-A1 | Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine | SEPRACOR, INC. | 2003-01-23 | — | — | US | disclosed |
| US-6441048-B1 | A (-)VENLAFAXINE DERIVATIVE OR A SALT FREE OF ITS (+)STEREO-ISOMER AND A CARRIER OR EXCIPIENT; SIDE EFFECT REDUCTION; ANTIDEPRESSANTS; ATTENTION DEFICIT DISORDER; HYPERACTIVITY. OBESITY; INHIBITION OF NEURONAL MONOAMINE REUPTAKE | SEPRACOR, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020086904-A1 | Methods of treating affective disorders using derivatives of (-)- venlafaxine | SEPRACOR INC. | 2002-07-04 | — | — | US | disclosed |
| US-6342533-B1 | ANTIDEPRESSANTS UDES FOR BIPOLAR AND ATTENTION DEFICIT DISORDERS, HYPERACTIVITY, PARKINSON'S DISEASE, EPILEPSY, EATING DISORDERS | SEPRACOR, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-1135358-A1 | DERIVATIVES OF (+)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | Sepracor Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6197828-B1 | NONTRICYCLIC ANTIDEPRESSANTS HAVE RECENTLY BEEN DEVELOPED THAT DIMINISH THE CARDIOVASCULAR AND ANTICHOLINERGIC LIABILITY, | SEPRACOR, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-2000032555-A1 | DERIVATIVES OF (+)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SEPRACOR INC. (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232157-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | COMT, MAOA, MAOB | SLC6A4 10/4885SLC6A3 5/4885SLC6A2 4/4885 |
| US-20040180952-A1 | Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same | COMT, MAOA, MAOB | SLC6A4 14/4885SLC6A3 5/4885SLC6A2 4/4885 |
| US-20030018083-A1 | Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine | COMT, MAOA, ACHE | SLC6A4 13/4885SLC6A3 6/4885SLC6A2 4/4885 |
| US-20120302794-A1 | Derivatives of venlafaxine and methods of preparing and using the same | COMT, MAOA, MAOB | SLC6A4 13/4885SLC6A3 6/4885SLC6A2 4/4885 |
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | COMT, MAOA, MAOB | SLC6A4 11/4885SLC6A3 5/4885SLC6A2 4/4885 |
| US-20020086904-A1 | Methods of treating affective disorders using derivatives of (-)- venlafaxine | COMT, MAOA, MAOB | SLC6A4 11/4885SLC6A3 6/4885SLC6A2 4/4885 |
| US-20140121283-A1 | METHODS OF USING DERIVATIVES OF (-)-VENLAFAXINE | COMT, MAOA, MAOB | SLC6A4 10/4885SLC6A3 5/4885SLC6A2 4/4885 |
| US-20080269166-A2 | DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | COMT, MAOA, MAOB | SLC6A4 13/4885SLC6A3 6/4885SLC6A2 4/4885 |
| US-20040106576-A1 | Derivatives of venlafaxine and methods of preparing and using the same | COMT, MAOA, MAOB | SLC6A4 13/4885SLC6A3 6/4885SLC6A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.